MetaCap

Innoviva (INVA) vs Nuvation Bio (NUVB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Innoviva (INVA) has outperformed Nuvation Bio (NUVB) over the past year, losing 12.2% versus a loss of 45.6%. Over five years, INVA leads with a +8.8% price change compared with -53.5% for NUVB. Nuvation Bio is the larger company by market cap ($1.34 billion vs $1.31 billion), about 1.0 times the size.

Innoviva converts more of its revenue into profit, with a net margin of 65.9% versus -325.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INVA-12.17%NUVB-45.64%
+41%-5%-50%
Nov 21, 20251 yearNov 20, 2026
INVA+7.98%NUVB-58.01%
+49%-23%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INVA versus NUVB key metrics
MetricINVANUVB
Share price$18.41$3.80
Market cap$1.31B$1.34B
1-day change0.00%-0.26%
YTD return-7.90%-57.59%
1-year return-12.17%-45.64%
5-year return+8.81%-53.49%
P/E ratio (TTM)7.83—
Forward P/E8.33—
EPS (TTM)$2.35$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$411.33M$62.90M
Revenue growth (YoY)+14.67%+698.96%
Net income (latest FY)$271.17M$-204.63M
Gross margin74.80%—
Operating margin39.81%-338.72%
Net margin65.92%-325.31%
52-week high$25.15$9.75
52-week low$18.19$3.71
Distance from 52-week high-26.80%-61.03%
Analyst consensusbuystrong_buy
Avg. price target upside+89.03%+227.63%
Average volume865.66K5.24M
Shares outstanding71.08M352.02M
Employees159310
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INVA has outperformed NUVB by 33.5 percentage points over the past year.
  • Innoviva is more profitable, keeping 65.9 cents of every revenue dollar as net income versus -325.3 cents for Nuvation Bio.
  • Nuvation Bio grew revenue faster in its latest fiscal year (+698.96% vs +14.67%).

About Innoviva

INVA stock →

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees

About Nuvation Bio

NUVB stock →

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees

INVA vs NUVB FAQ

Which is bigger, Innoviva or Nuvation Bio?

Nuvation Bio (NUVB) is larger, with a market capitalization of $1.34B compared with $1.31B for Innoviva (INVA).

Which stock has performed better over the past year, INVA or NUVB?

INVA returned -12.17% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.

Are Innoviva and Nuvation Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons